CAR T-Cell Therapy Market Size to Surpass USD 146.55 Billion by 2034 Fueled by Innovations in Cancer Treatment and Growing Demand for Personalized Therapies

Ottawa, Oct. 30, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global car t-cell therapy market size reached USD 5.51 billion in 2024 and is estimated to attain USD 146.55 billion by 2034, growing at a CAGR of 38.83% during the forecast period from 2025 to 2034. Robust product pipeline with regulatory approvals across geographies, increasing inclination towards targeted treatment, and growing cases of cancer malignancies across the population, driving the growth of the market.

This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.

Try Before You Buy – Get the Sample Report@ https://www.statifacts.com/stats/databook-download/8510

CAR T-Cell Therapy Market Highlights

North America led the CAR T-cell therapy market in 2024, holding a dominant revenue share of 49%, and is expected to maintain its leadership, driven by advanced healthcare infrastructure and robust investments in cancer treatment research.Asia-Pacific is projected to witness the fastest growth, with a remarkable CAGR of 40.22% from 2025 to 2034, fueled by increasing healthcare expenditure and advancements in cellular therapies in key regions such as China and India.The CD19 target antigen segment led the market in 2024, capturing a significant share of 63%, and is expected to maintain its dominance, owing to the widespread application of CD19-targeted therapies in treating hematologic cancers.The BCMA (B-cell maturation antigen) segment is anticipated to experience substantial growth, with an expected CAGR of 46.15% from 2025 to 2034, driven by its promising results in treating multiple myeloma and other blood cancers.The hematologic malignancies segment dominated the CAR T-cell therapy market in 2024, accounting for 94% of the market share, and is expected to continue leading, driven by the high efficacy of CAR-T therapies in treating blood cancers.The solid tumors segment is projected to grow at a significant CAGR of 45.68% from 2025 to 2034, fueled by increasing research and clinical trials aimed at expanding CAR-T therapy's applicability to solid cancer types.Autologous CAR-T cell therapy held the largest market share of 80% in 2024 and is expected to remain the preferred method, due to its personalized treatment approach and proven efficacy in patients with hematologic malignancies.Allogeneic CAR-T cell therapy is anticipated to grow at a notable CAGR of 44.35% from 2025 to 2034, driven by advancements in off-the-shelf therapies that offer more accessible and cost-effective treatment options.The viral vectors segment led the market in 2024, capturing a 66% share, and is expected to continue to dominate, as viral vectors are the most established method for delivering CAR-T cells into patients' immune systems.Centralized manufacturing dominated the CAR T-cell therapy market in 2024, holding a 54% market share, and is likely to maintain this position, driven by its streamlined production processes and quality control advantages.The in vivo CAR-T therapy segment is expected to experience rapid growth, with a projected CAGR of 47.28%, as it holds potential for reducing production time and improving the scalability of CAR-T therapies.The hospitals segment held a significant market share of 44% in 2024, and is anticipated to continue leading, driven by the increasing adoption of CAR-T therapies in clinical settings for cancer treatment.

CAR T-Cell Therapy Market Size, by Region, 2022 to 2026 (USD Million)

Region20222023202420252026North America1,409.801,950.032,698.763,735.995,173.29Europe671.81935.021,302.051,813.612,526.81Asia Pacific557.73781.951,096.751,538.512,158.52Latin America169.33226.63303.12405.01540.51Middle East & Africa61.3082.37110.64148.50199.16

CAR T-Cell Therapy Market Size, by Target Antigen, 2022 to 2026 (USD Million)

Region20222023202420252026CD191,907.982,570.133,461.034,657.846,264.21BCMA (B-cell Maturation Antigen)380.18575.60865.761,294.661,926.51CD22180.32252.40353.43495.01693.43GD298.96142.28204.43293.46420.94HER261.5092.12137.28203.67300.96GPC350.6075.85113.13167.95248.33Others (e.g., EGFRvIII, CD7, CD123, mesothelin)190.42267.63376.26529.04743.91

CAR T-Cell Therapy Market Size, by Indication / Disease Type, 2022 to 2026 (USD Million)

Region20222023202420252026Hematologic Malignancies2,723.163,755.395,181.637,151.379,872.40Solid Tumors146.80220.61329.70490.26725.89

CAR T-Cell Therapy Market Size, by Type of Therapy, 2022 to 2026 (USD Million)

Region20222023202420252026Autologous CAR T-cell Therapy2,369.603,239.394,430.166,059.298,288.36Allogeneic CAR T-cell Therapy500.37736.611,081.171,582.342,309.93

CAR T-Cell Therapy Market Size, by Technology / Vector Used, 2022 to 2026 (USD Million)

Region20222023202420252026Viral Vectors1,979.872,685.513,643.014,940.906,699.71Non-viral Vectors463.66674.45979.381,419.642,054.48Armored CAR T-Cells (enhanced T-cell persistence/activity)174.01256.37376.58551.55805.74Dual/Multiple Antigen Targeting CAR T-Cells179.30255.91365.15520.73742.23Safety Switch-Equipped CAR T Cells73.13103.75147.21208.82296.13

CAR T-Cell Therapy Market Size, by Manufacturing/Delivery Method, 2022 to 2026 (USD Million)

Region20222023202420252026Point-of-Care Manufacturing743.581,035.051,441.532,008.172,798.25Centralized Manufacturing1,585.402,165.052,957.644,040.625,520.46In vivo CAR T therapy (emerging)188.57292.24448.06680.831,026.89Off-the-shelf / Ready-to-use therapies352.42483.67664.10912.001,252.69

CAR T-Cell Therapy Market Size, by End Use, 2022 to 2026 (USD Million)

Region20222023202420252026Hospitals1,327.561,800.552,442.283,312.064,490.58Cancer Treatment Centers846.271,176.531,636.552,277.053,169.07Academic & Research Institutes372.47506.51688.94936.981,274.19Specialty Clinics162.67249.04378.03569.65853.17Contract Development and Manufacturing Organizations (CDMOs)161.00243.37365.53545.88811.28

Kindly use the following link to access our scheduled meeting@ https://www.statifacts.com/schedule-meeting

What is CAR T-Cell Therapy?

The CAR T-cell therapy market refers to the production, distribution, and use of CAR T-cell therapy, which is a cancer treatment that takes cells from the body and genetically changes them so they can fight cancer. It is most commonly used to treat cancers that affect blood cells, like specific types of leukemia, lymphoma, and multiple myeloma. CAR T-cell therapy is available for some children and adults with leukemia. The CARs help the cells to latch on to specific proteins, known as antigens, that are present on cancer cells.

CAR T-cells can cure specific types of blood cancer. The benefit of CAR T-cell therapy is the short treatment time required for completion. It scores over the other traditional cancer treatments in long-term remission with a better quality of life for the patient. CAR T-cell therapy modifies a patient's T-cells to target and destroy cancer cells.

Major Government Initiatives in CAR T-Cell Therapies:

France 2030 – Universal CAR-T Grant to Allogenica: Under the French government’s Innovations in Biotherapies and Bioproduction component of the France 2030 program, Allogenica was awarded a €2.5 million grant to industrialize a universal (allogeneic) CAR-T platform. This aims to boost scalability, reduce costs, and strengthen France’s domestic biomanufacturing ecosystem for CAR-T therapies.The Netherlands’ “CAR-TB-CURE” Clinical Study for Autoimmune Diseases: The Dutch National Healthcare Institute and the research council (ZonMw) are funding (~€14.6 million) a six-year project spearheaded by Leiden University Medical Center and Amsterdam UMC to investigate CAR-T therapy for severe autoimmune diseases. The “CAR-TB-CURE” initiative also aims to address issues of safety, cost-effectiveness, and accessibility evaluating whether academic/hospital-produced CAR-T can be part of standard care.Germany: BMBF Funding for New CAR-T Targets (CXCR5) in Lymphoma: Germany’s Federal Ministry of Education and Research (BMBF) is funding (€4.6 million) a joint project by Charité and the Max Delbrück Center to push a novel CAR-T target (CXCR5) into human trials for B-non-Hodgkin’s lymphoma. This helps stimulate early-stage innovation in antigen discovery and preclinical/clinical translation.England / NHS Expansion of CAR-T Access via Cancer Drugs Fund: NHS England has struck new funding and policy deals allowing personalized CAR-T treatments (e.g., axicabtagene ciloleucel, etc.) to be made more widely available for eligible patients through the Cancer Drugs Fund (CDF). This increases patient access by enabling reimbursement and setting protocols for broader eligibility in certain blood cancers.EU / European Innovation Council (EIC) Support for Clinical Trials: Through EU-level funding mechanisms (like the European Innovation Council’s Accelerator programme), governments are financing CAR-T clinical trials to de-risk early development. An example is Elicera Therapeutics getting €2.5 million from EIC to fully fund its phase I/II trial (ELC-301) for treating B-cell lymphoma.

What are the Key Trends of the CAR T-Cell Therapy Market?

Expansion into Solid Tumors: While CAR T-cell therapies have shown strong success in blood cancers, researchers are now applying them to solid tumors like glioblastoma and lung cancer. Overcoming tumor microenvironments and antigen heterogeneity is a major focus of ongoing clinical trials.Development of Allogeneic (Off-the-Shelf) Therapies: Allogeneic CAR-T uses donor cells, offering faster treatment and lower costs compared to patient-specific (autologous) therapies. This approach enables mass production and addresses limitations like manufacturing delays and variability.Advancements in Manufacturing Technologies: Automation, AI, and closed-system manufacturing are streamlining CAR-T production, improving consistency and scalability. These innovations are reducing costs and turnaround times, which are critical for broader market adoption.Earlier-Line Treatment Approvals: Regulatory bodies are approving CAR-T therapies for use earlier in the treatment journey, such as second-line settings. This shift significantly expands the eligible patient population and increases commercial potential.Global Market Expansion and Regional Innovation: The CAR-T market is rapidly growing in the Asia-Pacific regions, with China and South Korea emerging as innovation hubs. Local companies and favorable regulatory environments are accelerating development and access to therapies.

Case Study: Gilead Sciences & Arcellx – Redefining CAR T-Cell Therapy Through Next-Generation BCMA Innovation

CAR T-cell therapy, once an experimental treatment for rare blood cancers, has rapidly evolved into one of the most promising frontiers in oncology. Among the therapeutic targets, B-cell maturation antigen (BCMA) has emerged as a crucial focus for addressing relapsed or refractory multiple myeloma (RRMM). This market segment is witnessing exceptional growth, projected to register a CAGR of over 46% from 2025 to 2034, driven by novel therapies demonstrating improved efficacy, scalability, and patient outcomes.

In this context, Gilead Sciences (via its Kite Pharma subsidiary) and Arcellx Inc. have formed one of the most strategically impactful alliances in the CAR-T ecosystem. Their lead investigational product, anito-cel (formerly known as CART-ddBCMA), represents a new generation of CAR T-cell therapy targeting BCMA with enhanced safety and durability of response.

Challenge:

Despite remarkable success in hematologic malignancies, CAR T-cell therapies have faced three key limitations:

Safety risks such as cytokine release syndrome (CRS) and neurotoxicity.Manufacturing delays associated with autologous CAR T production, leading to treatment bottlenecks.Short duration of remission, especially in patients with advanced or refractory myeloma.

Patients who relapse after prior CAR-T treatments often have limited options, creating a clinical and commercial need for safer, longer-lasting, and more scalable CAR T-cell products.

Solution:

Arcellx’s proprietary ARC-SparX platform introduced a modular CAR design that allows precise activation of engineered T cells only in the presence of a matching antigen-binding “SparX” protein. This innovation provides:

Improved safety control (reduces off-tumor toxicity and cytokine storms).Flexible reactivation (enables re-dosing for sustained therapeutic effects).Simplified manufacturing with enhanced cell viability.

Gilead Sciences, leveraging its commercial and regulatory infrastructure, partnered with Arcellx in December 2022, investing over USD 225 million upfront and later expanding the deal to USD 1.25 billion to co-develop and co-commercialize anito-cel globally.

Implementation:

The collaboration moved rapidly through the clinical development phase.

In November 2024, Gilead and Arcellx presented updated Phase 2 trial data at the American Society of Hematology (ASH) Annual Meeting.95% overall response rate (ORR) and 62% complete or stringent complete response (CR/sCR) were reported among 58 patients with RRMM.Median follow-up: 10.3 months.Safety profile: No delayed neurotoxicity, reduced cytokine release incidents compared to earlier CAR T versions.

Manufacturing efficiency also improved, with turnaround times reduced by nearly 30%, enhancing patient access.

Results:

Key MetricsAnito-cel (Arcellx + Gilead)Industry Benchmark (Average)Overall Response Rate (ORR)95%70–80%Complete Response (CR/sCR)62%35–45%Median Duration of Response>12 months (projected)8–10 monthsSevere CRS Incidence